header advert
Results 1 - 3 of 3
Results per page:
Orthopaedic Proceedings
Vol. 105-B, Issue SUPP_17 | Pages 42 - 42
24 Nov 2023
Tessier E d'Epenoux Louise R Lartigue M Guerin F Plouzeau-Jayle C Tandé D Chenouard R Bemer P Corvec S
Full Access

Abstract Background

The treatment of bone and joint infections (BJI) involving multi-drug resistant bacteria remains a challenge. MDR Staphylococcus epidermidis (MDRSE) clones, resistant to methicillin, clindamycin, levofloxacin, rifampicin and even linezolid, have been reported worldwide. The interest of delafloxacin (DFX), theoretically active on MRSA, remains to be evaluated with respect to MDRSE.

Purpose

Our objective was to evaluate during a retrospective multicenter study the DFX minimal inhibitory concentrations (MICs) and compare its efficacy between ofloxacin-susceptible and ofloxacin-resistant S. epidermidis clinical strains involved in BJI.


Orthopaedic Proceedings
Vol. 105-B, Issue SUPP_17 | Pages 66 - 66
24 Nov 2023
d'Epenoux Louise R Robert M Caillon H Crenn V Dejoie T Lecomte R Tessier E Corvec S Bemer P
Full Access

Background

The diagnosis of periprosthetic joint infection (PJI) remains a challenge in clinical practice and the analysis of synovial fluid (SF) is a useful diagnostic tool. Recently, two synovial biomarkers (leukocyte esterase (LE) strip test, alpha-defensin (AD)) have been introduced into the MSIS (MusculoSkeletal Infection Society) algorithm for the diagnosis of PJI. AD, although promising with high sensitivity and specificity, remains expensive. Calprotectin is another protein released upon activation of articular neutrophils. The determination of calprotectin and joint CRP is feasible in a routine laboratory practice with low cost.

Purpose

Our objective was to evaluate different synovial biomarkers (calprotectin, LE, CRP) for the diagnosis of PJI.


Orthopaedic Proceedings
Vol. 104-B, Issue SUPP_10 | Pages 4 - 4
1 Oct 2022
Dupieux C Dubois A Loiez C Marchandin H Lavigne JP Munier C Chanard E Gazzano V Courboulès C Roux A Tessier E Corvec S Bemer P Laurent F Roussel-Gaillard T
Full Access

Aim

Bone and joint infections (BJIs) are serious infections requiring early optimized antimicrobial therapy. BJIs can be polymicrobial or caused by fastidious bacteria, and the patient may have received antibiotics prior to sampling, which may decrease the sensitivity of culture-based diagnosis. Furthermore, culture-based diagnosis can take up to 14 days. Molecular approaches can be useful to overcome these concerns. The BioFire® system performs syndromic multiplex PCR in 1 hour, with only a few minutes of sample preparation. The BioFire® Joint Infection (JI) panel (BF-JI), recently FDA-cleared, detects both Gram-positive (n=15) and Gram-negative bacteria (n=14), Candida, and eight antibiotic resistance genes directly from synovial fluids. The aim of this study was to evaluate its performance in acute JIs in real-life conditions.

Method

BF-JI was performed on synovial fluid from patients with clinical suspicion of acute JI, either septic arthritis or periprosthetic JI, in 6 French centers. The results of BF-JI were compared with the results of culture of synovial fluid and other concomitantly collected osteoarticular samples obtained in routine testing in the clinical microbiology laboratory.